News
Find all the latest news from Frontier Science Scotland below
choose a category:
ALEXANDRA | Journal of the American Medical Association (JAMA)
The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.
ALTTO | ESMO Open
Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.
APHINITY | Journal of Clinical Oncology
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Keep CAALM and Carry On Doing Clinical Trials
Enabling excellence in clinical trial research services through collaborative working.
Frontier Science Scotland Strengthens Board of Trustees
Learn how Frontier Science Scotland’s flexible approach delivers exceptional results for clients in industry >>
Catalysing Excellence in Industry Trials
Learn how Frontier Science Scotland’s flexible approach delivers exceptional results for clients in industry >>
Ensuring exceptional service delivery for partners in academia
Discover how Frontier Science Scotland best serves clients in academia – featuring insights from Dr Shona Fielding, Head of Biostatistics >>
Spotlight on NordICC for Colorectal Cancer Awareness Month
For Colorectal Cancer Awareness Month, discover Frontier Science Scotland’s involvement in related studies, such as NordICC >>
Meet Dr Sarah Barry, Statistics Team Lead
Delve into Sarah’s impressive career. Discover what she likes about working at Frontier Science Scotland and her experience of being a woman in STEM >>
Meet Marion Procter, Senior Statistician
We find out what led our senior statistician, Marion Procter, to a career in statistics, and discover her work on the HERA trial.
HERA
The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>
Why we give our employees two volunteering days each year
Discover the diverse projects our employees have been using their volunteering leave for
Our 15+ Years of Auditing NHS Scotland Research Projects
We’ve been providing auditing services to NHS Scotland since 2007. Read on to find out how we have contributed to improvements in Scottish hospital research sites…
How we’re building an inclusive, open culture around mental health
We work hard to create an inclusive, open culture around mental health at FSS. Find out the steps we’re taking this Mental Health Awareness Week (and year round)…
Supporting an academic clinical trials unit to meet study deadlines
How our biostatistics team was able to step in to seamlessly fill capacity gaps and ensure no study deadlines were missed.
OlympiA results in the subset of patients from Japan
The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.
How our data management experience and risk-based approach benefit clinical trial monitoring
Find out how our risk-based and flexible approach to monitoring helped deliver a complete and accurate database in a Norwegian clinical trial
Successfully Merging Two Databases Into One
How our flexibility, bespoke data review processes and collaborative approach led to outstanding and practice-changing results in a global breast cancer clinical trial
An Agile Approach to Statistical Analysis
How we developed an agile approach to statistical analyses for a clinical trial while the study protocol was still being amended
Cardiac Safety in the APHINITY trial
ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.
Let's work together
Simply fill in this quick form and we’ll be back in touch within the next two working days. Alternatively, you can call us during usual business hours or send us an email.